Objective:To investigate the effects of persistent isolated hypothyroxinemia in the first and second trimester of pregnancy on complications and adverse outcomes of pregnancy.Methods:A retrospective analysis was conducted in 784 pregnant women including 111 cases of persistent isolated hypothyroxinemia in the first and second trimester of pregnancy and 673 pregnant women with normal thyroid function as control group. All women were registered and delivered in the Department of Obstetrics of our hospital from April 2016 to April 2017. The complications and adverse outcomes of pregnancy in the two groups were analyzed.Results:Age, body weight before pregnancy, body mass index(BMI), 1 h plasma glucose and 2 h plasma glucose during oral glucose tolerance test in persistent isolated hypothyroxinemia group were higher than those in control group( P<0.05), with increased incidence of anemia during pregnancy( P<0.05). However, there were no significant differences in the incidences of gestational diabetes mellitus and gestational hypertension between the two groups( P>0.05). No significant statistical differences were found in macrosomia, stillbirth, neonatal malformation, postpartum hemorrhage, acute delivery, premature delivery, fetal intrauterine development delay, and small full-term infants between the two groups( P>0.05). Logistic regression analysis showed that age( OR=1.1, 95% CI 1.0-1.1, P=0.002) and pre-pregnancy body weight( OR=1.0, 95% CI 1.0-1.1, P=0.046) were risk factors for the occurrence of persistent isolated hypothyroxinemia in the first and second trimesters of pregnancy. Persistent isolated hypothyroxinemia in the first and second trimesters was associated with anemia during pregnancy( OR=1.9, 95% CI 1.1-3.2, P=0.024). Conclusions:Pregnant women who are older and heavier before pregnancy should pay more attention to their thyroid function. Pregnant women with persistent isolated hypothyroxinemia in the first and second trimesters should be concerned for anemia.

This paper reports a case of a male patient with diabetes for more than 20 years who came to see doctor due to weakness, poor appetite and significantly elevated blood glucose. At first, it was considered that the poor blood glucose control of diabetes was the reason, and the possibility of diabetes related complications already existed. Hospital routine examination indicated a globulin increase and immunologic examination indicated that IgM was mainly increased. Subsequent imageological diagnosis revealed a small amount of bilateral pleural effusion, and after 2 weeks of hypoglycemic treatment, the blood glucose was significantly improved, but the symptoms still existed. In combination with the patient' s laboratory examination, considering the combination of blood system diseases, the hematology department was invited for consultation. Immunoelectrophoresis, bone marrow cytology, and flow cytometry were further conducted, and the patient was diagnosed with Waldenstrom macroglobulinebia. Bortezomib+dexamethasone regimen was given for chemotherapy. Currently, the patient has received 1 course of chemotherapy, and the symptoms of poor appetite were significantly improved. Coexistence of diabetes mellitus and Waldenstrom macroglobulinebia is very rare in clinical practice, and it is easy to be misdiagnosed as a complication of diabetes mellitus, both of which can be manifested as poor appetite, weakness, peripheral neuropathy and other symptoms. When diabetic patients have abnormal immunoglobulin increases and other abnormal test results that cannot be well explained by diabetes, other potential disorders, such as hematological diseases, should be considered to avoid missed diagnosis.

目的 探讨难治性高血压患者的临床特点.方法 纳入2012年1月～2013年12月于我院内分泌代谢科就诊的高血压患者320例,依据难治性高血压的诊断标准将其分为高血压组269例和难治性高血压组51例.收集两组患者的临床资料并进行比较分析.结果 难治性高血压患者占总高血压患者的15.9％ (51/320).难治性高血压组患者病程长于高血压组,收缩压(SBP)、舒张压(DBP)及醛固酮水平均高于高血压组(P＜0.05),而两组患者性别、年龄、体重指数(BMI)、心率、QT间期、血钾、血钠、二氧化碳结合力比较,差异均无统计学意义(P＞0.05).难治性高血压组使用可乐定、α-受体阻滞剂、螺内酯、氢氯噻嗪、吲达帕胺、血管紧张素受体Ⅱ阻断剂(ARB)及钙离子拮抗剂(CCB)患者比例均高于高血压组(P＜0.05),而两组间使用β-受体阻滞剂和血管紧张素转化酶抑制剂(ACEI)患者比例比较差异均无统计学意义(P＞0.05).难治性高血压组合并糖尿病、冠心病、慢性肾脏病、高尿酸血症、肾上腺CT见腺瘤改变患者比例及颈动脉内膜厚度高于高血压组(P＜0.05),而两组间合并血脂异常、脑卒中患者比例比较差异均无统计学意义(P＞0.05).结论 难治性高血压患者占总高血压患者的比例较高,且常合并多种心血管危险因素及心脏、肾脏、肾上腺疾病.